GSK plc (GSK)

NYSE · London, United Kingdom · Founded 1715 · CEO Luke Miels

Valuation summary

$75.48 fair value versus $47.82 in the market, a difference of +57.8%. Rated Strong Buy.

Fair value per share$75.48
Current share price$47.82
Upside / downside+57.8%
Bear case$47.33
Bull case$115.55
Discount rate (WACC)8.4%
Terminal growth2.20%
Market capitalisation$75B
EV / Sales2.9x

About GSK plc

Traces to a London apothecary founded in 1715, with the modern company formed by the 2000 GlaxoWellcome and SmithKline Beecham merger. Emma Walmsley, CEO from 2017, separated consumer health as Haleon in 2022; Luke Miels, previously chief commercial officer, succeeded her as chief executive on 1 January 2026. GSK now focuses on vaccines, HIV through its ViiV stake, and specialty medicines. US-listed as an ADR.

Investment case

  • Shingrix is the leading shingles vaccine with a large under-penetrated eligible population.
  • The HIV franchise generates substantial and durable cash flow.
  • One of the higher dividend yields in large-cap pharmaceuticals.

Key risks

  • Zantac litigation created years of overhang, and legal risk in pharma rarely fully clears.
  • The oncology pipeline still lags larger peers, although Jemperli's FDA priority review in rectal cancer and the September 2026 Chimagen myeloma deal show it is being rebuilt.
  • Vaccine demand proved more cyclical post-pandemic than expected.

Recent developments

Revenue by segment

Specialty Medicines40%
Vaccines33%
General Medicines27%

Five-year forecast

RevenueFree cash flow
Year 1$34.7B$8.3B
Year 2$36.2B$8.4B
Year 3$37.8B$8.6B
Year 4$39.4B$8.8B
Year 5$41.1B$8.9B

What the street says

A value case in European pharma, now under Luke Miels, who became chief executive on 1 January 2026. Pipeline news flow between August and October 2026 has been positive, including a Phase III start for an mRNA flu vaccine and a CROWN trial win for long-acting HIV therapy Cabenuva. Vaccine growth and pipeline delivery remain the recurring debates.

Comparable companies: TAK · PFE · ZTS · BMY · BIIB · TEVA · DHR · NVO

Open the interactive model, price chart and sensitivity grid →